An article in the Wall Street Journal (14 Aug 2008) discussed a medical study carried out by the Boston Scientific Corp. (BSC) on a new heart stent called the Liberte that BSC wanted to introduce in the U.S. market. In the study, the company tested the Liberte on a random sample of 871 heart patients, 70 of whom suffered re-clogging in their hearts. Based on this sample data, compute a 95% CI for the population proportion of heart patients who use the Liberte stent and will experience re-clogging.(An additional note that is NOT relevant for computing your CI: The article also discusses how in another study involving 991 patients, who had used another stent currently in use called the Express, 7% of the patients had experienced reclogging. If you compare this 7% re-clogging rate of the Express to the CI that you get for the Liberte, you will see that there does not seem to be evidence that the Liberte is actually an improvement on the Express. The article then discusses how the FDA allows weaker standards when approving new medical devices as compared to the standards imposed when approving new drugs)